3-diarylmethylenes and uses thereof
US12398103B2 · kind B2 · utility
0Cited by
1References
9Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 19, 2021 |
| Grant date | Aug 26, 2025 |
| Priority date | — |
| Expiry date | Apr 6, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D211/96
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
3-Diarylmethylenes are disclosed. The compounds activate PP2A, suppress oncogenic kinase signaling, and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.